MCID: ANG054
MIFTS: 69

Angina Pectoris

Categories: Blood diseases, Cardiovascular diseases, Oral diseases, Rare diseases

Aliases & Classifications for Angina Pectoris

MalaCards integrated aliases for Angina Pectoris:

Name: Angina Pectoris 42 39 38 17
Prinzmetal's Variant Angina 12 77 54 74
Prinzmetal Angina 12 54 13 15
Variant Angina 12 54 56
Coronary Artery Vasospasm 54 74
Angina Pectoris, Variant 45 74
Prinzmetal's Angina 12 17
Angina Inversa 12 54
Angina 44 64
Variant Angina Pectoris 12
Vasospastic Angina 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0111151
KEGG 38 H01632
MeSH 45 D000788
ICD10 34 I20 I20.1 I20.9

Summaries for Angina Pectoris

NIH Rare Diseases : 54 Prinzmetal's variant angina (PVA) is characterized by recurrent episodes of chest pain (angina) that usually occur when a person is at rest, between midnight and early morning. "Typical" angina, by contrast, is often triggered by physical exertion or emotional stress. Episodes of PVA can be very painful, and may last from several minutes to thirty minutes. In some cases the pain may spread from the chest to the head, shoulder, or arm. The pain associated with PVA is caused by a spasm in the arteries that supply blood to the heart muscle (coronary arteries). This results in an obstruction of blood flow. In some people, persistent spasms increase the risk for serious complications such as a life-threatening arrhythmia or heart attack. PVA most commonly occurs in people who smoke and people who have high cholesterol or high blood pressure. In many cases it occurs for unknown reasons in otherwise healthy people. In some cases it may be triggered by alcohol withdrawal, stress, exposure to cold, certain medications, or use of stimulants such as cocaine. The diagnosis of PVA involves findings on an electrocardiogram, evidence of the spasms on angiogram, and relief of sudden symptoms with medicines called nitrates. Treatment during an episode to relieve pain and shorten its duration involves sublingual nitroglycerin (a nitrate). Treatment to reduce the frequency of episodes and possibly reduce the risk of serious complications involves calcium channel blockers or long-acting nitrates. For people with PVA who smoke, quitting smoking can lead to a significant decrease in the frequency of episodes. While most people with PVA do not experience serious complications, it is a chronic condition that needs to be monitored over time.

MalaCards based summary : Angina Pectoris, also known as prinzmetal's variant angina, is related to ischemia and intermittent claudication, and has symptoms including other and unspecified angina pectoris An important gene associated with Angina Pectoris is EDN1 (Endothelin 1), and among its related pathways/superpathways are Selenium Micronutrient Network and Fluid shear stress and atherosclerosis. The drugs Covera-HS and Nitroglycerin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A coronary artery vasospasm characterized by spasms of the coronary arteries that occur while at rest, generally late at night or early in the morning, resulting in severe chest pain with preserved exercise capacity.

MedlinePlus : 44 Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back. Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina: Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help. Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 64 About angina: Angina (an-JI-nuh or AN-juh-nuh) is chest pain or discomfort that occurs if an area of your heart muscle doesn't get enough oxygen-rich blood.Angina may feel like pressure or squeezing in your chest. The pain also can occur in your shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion.Angina isn't a disease; it's a symptom of an underlying heart problem. Angina usually is a symptom of coronary heart disease (CHD).CHD is the most common type of heart disease in adults. It occurs if a waxy substance called plaque (plak) builds up on the inner walls of your coronary arteries. These arteries carry oxygen-rich blood to your heart.

Wikipedia : 77 Variant angina, often termed Prinzmetal''s angina, Prinzmetal angina (/ˈprɪnts-/), and less commonly... more...

Related Diseases for Angina Pectoris

Diseases related to Angina Pectoris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 448)
# Related Disease Score Top Affiliating Genes
1 ischemia 31.5 ACE EDN1 NOS3 PLAT
2 intermittent claudication 30.9 ACE CRP IL6 SERPINC1
3 coronary artery vasospasm 30.7 EDN1 NOS3 PIK3C2A
4 intermediate coronary syndrome 30.5 ACE CRP IL6 PIK3C2A PLAT SERPINC1
5 aortic valve disease 2 30.5 ACE CRP NPPB
6 anterolateral myocardial infarction 30.5 ACE NPPB PLAT
7 coronary restenosis 30.4 ACE SERPINC1
8 arteriosclerosis 30.4 ACE APOA1 CRP EDN1 IL6
9 lipid metabolism disorder 30.3 ACE APOA1 CRP
10 pericarditis 30.3 CRP IL6 NPPB
11 inferior myocardial infarction 30.3 NPPB PIK3C2A PLAT
12 congestive heart failure 30.3 ACE ADRB1 EDN1 NPPB
13 kawasaki disease 30.3 CRP IL6 NPPB
14 dressler's syndrome 30.2 CRP PLAT
15 cardiac arrest 30.2 ACE NPPB PIK3C2A
16 myocarditis 30.2 IL6 NPPB TNNI3
17 pulmonary disease, chronic obstructive 30.2 CRP IL6 NPPB
18 gas gangrene 30.2 PIK3C2A TNNI3
19 left bundle branch hemiblock 30.1 ACE NPPB TNNI3
20 behcet syndrome 30.1 CRP IL6 SERPINC1
21 myocardial stunning 30.1 EDN1 SERPINC1 TNNI3
22 intracranial embolism 30.1 PLAT SERPINC1
23 peripheral vascular disease 30.0 ACE APOA1 CRP IL6 PLAT SERPINC1
24 ischemic heart disease 30.0 ACE APOA1 CRP IL6 NOS3 NPPB
25 peripheral artery disease 30.0 ACE CRP IL6 NOS3
26 apnea, obstructive sleep 29.9 CRP EDN1 IL6
27 diabetes mellitus 29.9 ACE APOA1 CRP EDN1 IL6 NOS3
28 coronary stenosis 29.9 ACE APOA1 CRP IL6 NPPB PIK3C2A
29 atherosclerosis susceptibility 29.9 APOA1 CRP IL6 NOS3
30 aortic coarctation 29.8 ACE ADRB1 EDN1 NOS3
31 thrombocytosis 29.8 CRP IL6 SERPINC1
32 purpura 29.8 CRP IL6 SERPINC1
33 arteries, anomalies of 29.8 ACE APOA1 CRP EDN1 IL6 NOS3
34 orthostatic intolerance 29.8 ADRB1 EDN1 NOS3
35 atrial fibrillation 29.7 ACE ADRB1 CRP NPPB PLAT
36 stroke, ischemic 29.7 ACE CRP NOS3 PLAT SERPINC1
37 pulmonary embolism 29.7 CRP NPPB PLAT SERPINC1 TNNI3
38 connective tissue disease 29.7 ACE EDN1 IL6
39 renovascular hypertension 29.6 ACE EDN1 NOS3
40 atrial standstill 1 29.6 ACE ADRB1 NPPB TNNI3
41 acute myocardial infarction 29.5 ACE ADRB1 APOA1 CRP EDN1 NPPB
42 cardiogenic shock 29.5 IL6 NPPB PIK3C2A PLAT
43 sleep apnea 29.4 ACE CRP EDN1 IL6 NOS3 NPPB
44 hypercholesterolemia, familial 29.4 ACE APOA1 APOA2 CRP NOS3
45 vascular disease 29.3 ACE APOA1 CRP EDN1 IL6 NOS3
46 cerebrovascular disease 29.3 ACE APOA1 CRP IL6 PLAT
47 systolic heart failure 29.3 ACE ADRB1 CRP EDN1 IL6 NPPB
48 coronary artery anomaly 29.3 ACE ADRB1 APOA1 CRP EDN1 NOS3
49 pulmonary hypertension 29.1 ACE EDN1 HTR1B NOS3 NPPB PLAT
50 diabetes mellitus, noninsulin-dependent 29.1 ACE APOA1 APOA2 CRP EDN1 IL6

Comorbidity relations with Angina Pectoris via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Esophagitis
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease

Graphical network of the top 20 diseases related to Angina Pectoris:



Diseases related to Angina Pectoris

Symptoms & Phenotypes for Angina Pectoris

UMLS symptoms related to Angina Pectoris:


angina pectoris, other and unspecified angina pectoris

MGI Mouse Phenotypes related to Angina Pectoris:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ACE ADRB1 APOA1 CRP EDN1 HTR1B
2 homeostasis/metabolism MP:0005376 10 ACE ADRB1 APOA1 APOA2 CRP EDN1
3 endocrine/exocrine gland MP:0005379 9.97 ACE ADRB1 APOA1 EDN1 HTR1B IL6
4 growth/size/body region MP:0005378 9.97 ACE ADRB1 APOA2 EDN1 HTR1B IL6
5 adipose tissue MP:0005375 9.91 ACE ADRB1 HTR1B IL6 NOS3 PIK3C2A
6 mortality/aging MP:0010768 9.85 ACE ADRB1 EDN1 HTR1B IL6 NOS3
7 muscle MP:0005369 9.5 ADRB1 EDN1 HTR1B IL6 NOS3 PLAT
8 renal/urinary system MP:0005367 9.1 ACE EDN1 IL6 NOS3 PIK3C2A SERPINC1

Drugs & Therapeutics for Angina Pectoris

PubMedHealth treatment related to Angina Pectoris: 64

Treatments for angina include lifestyle changes, medicines, medical procedures, cardiac rehabilitation (rehab), and other therapies. The main goals of treatment are to:Reduce pain and discomfort and how often it occursPrevent or lower your risk for heart attack and death by treating your underlying heart conditionLifestyle changes and medicines may be the only treatments needed if your symptoms are mild and aren't getting worse. If lifestyle changes and medicines don't control angina, you may need medical procedures or cardiac rehab.Unstable angina is an emergency condition that requires treatment in a hospital.

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Covera-HS 19 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996

Drugs for Angina Pectoris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 672)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-63-0 4510
2
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 134523-00-5 60823
3
Atenolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29122-68-7 2249
4
Nicorandil Approved, Investigational Phase 4,Phase 2,Not Applicable 65141-46-0 47528
5
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95635-55-5, 142387-99-3 56959
6
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 58-22-0, 481-30-1 10204 6013
7
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2 315-37-7 9416
8
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2 5949-44-0
9
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
10
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 50-78-2 2244
11
Pravastatin Approved Phase 4,Phase 3,Not Applicable 81093-37-0 54687
12
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
13
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 58-61-7 60961
14
Amiodarone Approved, Investigational Phase 4,Not Applicable 1951-25-3 2157
15
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable 88150-42-9 2162
16
Diltiazem Approved, Investigational Phase 4,Not Applicable 42399-41-7 39186
17
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Not Applicable 145040-37-5 2540
18
Bisoprolol Approved Phase 4,Phase 2,Not Applicable 66722-44-9 2405
19
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
20
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
21
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
22
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
23
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 72956-09-3 2585
24
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
25
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
26
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
27
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 46507594 772
28
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
29
Chromium Approved Phase 4,Phase 2,Phase 3,Not Applicable 7440-47-3 27668
30
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 7440-48-4 104729
31 Nutmeg Approved Phase 4,Phase 3,Phase 2,Not Applicable
32
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
33
Telmisartan Approved, Investigational Phase 4,Not Applicable 144701-48-4 65999
34
Amiloride Approved Phase 4,Phase 2,Phase 3,Not Applicable 2609-46-3, 2016-88-8 16231
35
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
36
Gliclazide Approved Phase 4,Early Phase 1 21187-98-4 3475
37
Glyburide Approved Phase 4,Phase 1 10238-21-8 3488
38
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 657-24-9 14219 4091
39
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
40
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
41
Valsartan Approved, Investigational Phase 4,Phase 3,Not Applicable 137862-53-4 60846
42
Citalopram Approved Phase 4,Phase 1,Phase 2,Not Applicable 59729-33-8 2771
43
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
44
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 70789204 6442177
45
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
46
Tirofiban Approved Phase 4,Phase 3,Phase 2 144494-65-5 60947
47
Tenecteplase Approved Phase 4 191588-94-0
48
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 2833 6167
49
Etanercept Approved, Investigational Phase 4 185243-69-0
50
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 73963-72-1 2754

Interventional clinical trials:

(show top 50) (show all 1871)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
2 Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina Unknown status NCT02280850 Phase 4 Guanxin Shutong Capsule;Placebo Capsule;nitroglycerine
3 Spinal Cord Stimulation (SCS) in Refractory Angina Unknown status NCT00121654 Phase 4
4 The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
5 Efficacy Study of Atorvastatin to Treat Variant Angina Unknown status NCT00620204 Phase 4 atorvastatin
6 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
7 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR) Unknown status NCT03044964 Phase 4 Ranolazine;Placebo
8 Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido
9 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
10 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
11 Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Unknown status NCT02284048 Phase 4 ticagrelor
12 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
13 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
14 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes Unknown status NCT02126202 Phase 4
15 Treatment of Reperfusion Event by Vitamin C Infusion Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
16 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
17 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
18 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
19 Small Coronary Artery Treated by TAXUS Liberté Registry in Japan Unknown status NCT00955214 Phase 4
20 Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
21 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
22 Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
23 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
24 Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
25 Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
26 Efficacy Study of Nicorandil on Neointima Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
27 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
28 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
29 DEDICA (Dose of HEparin During Coronary Angioplasty) Trial Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
30 Ranolazine Loading to Prevent PCI-induced Myocardial Injury Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
31 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
32 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
33 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
34 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
35 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
36 Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study Unknown status NCT00688922 Phase 4 Pravastatin
37 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
38 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
39 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
40 Ranolazine for Improving Symptoms of Palpitations Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
41 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
42 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
43 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
44 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
45 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
46 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4 valsartan
47 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
48 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
49 Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI) Unknown status NCT01115842 Phase 4 Vitamin D
50 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.

Search NIH Clinical Center for Angina Pectoris

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: angina pectoris, variant

Genetic Tests for Angina Pectoris

Anatomical Context for Angina Pectoris

MalaCards organs/tissues related to Angina Pectoris:

42
Heart, Testes, Endothelial, Kidney, Spinal Cord, Bone, Lung

Publications for Angina Pectoris

Articles related to Angina Pectoris:

(show top 50) (show all 3211)
# Title Authors Year
1
Adherence to the Healthy Nordic Food Index and the incidence of acute myocardial infarction and mortality among patients with stable angina pectoris. ( 30091209 )
2019
2
Intramural Coronary Amyloidosis Mimicking Effort Angina Pectoris Preceding Fatal Heart Failure. ( 30197408 )
2019
3
A multicenter trial of extracorporeal cardiac shock wave therapy for refractory angina pectoris: report of the highly advanced medical treatment in Japan. ( 29942978 )
2019
4
An unusual cause of angina pectoris due to dynamic coronary artery compression and successful treatment with cardiac surgical reconstruction. ( 30053112 )
2019
5
Atypical angina pectoris: the compressed graft. ( 30083857 )
2019
6
Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and/or unprotected left main disease. ( 30143922 )
2019
7
Experiences of Undergoing Enhanced External Counterpulsation in Patients With Refractory Angina Pectoris: A Qualitative Study. ( 30273260 )
2019
8
Effects of thoracic epidural analgesia on exercise-induced myocardial ischaemia in refractory angina pectoris. ( 30374950 )
2019
9
3D-speckle tracking echocardiography for assessment of coronary artery disease severity in stable angina pectoris. ( 30515893 )
2019
10
Serum levels of homocysteine and circulating antioxidants associated with heart rate variability in patients with unstable angina pectoris. ( 30628966 )
2019
11
Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials. ( 30653160 )
2019
12
Economic Outcomes and Geographic Trending in Patients With Limiting Angina Pectoris. ( 30661721 )
2019
13
A decline in the prevalence of angina pectoris: Data from the Nutrition and Health Survey in Taiwan. ( 30685101 )
2019
14
Acupuncture therapy for the treatment of stable angina pectoris: An updated meta-analysis of randomized controlled trials. ( 30712735 )
2019
15
Automatic Estimation of Coronary Blood Flow Velocity Step 1 for Developing a Tool to Diagnose Patients With Micro-Vascular Angina Pectoris. ( 30740396 )
2019
16
Identification Potential Plasma Biomarkers and Metabolic Dysfunction for Unstable Angina Pectoris and Its Complication based on Global Metabolomics. ( 30770400 )
2019
17
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics. ( 30771737 )
2019
18
Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. ( 30771861 )
2019
19
Effectiveness of Long-acting Trimetazidine in Different Clinical Situations in Patients with Stable Angina Pectoris: Findings from ODA Trial. ( 30778909 )
2019
20
Compound salvia pellet might be more effective and safer for chronic stable angina pectoris compared with nitrates: A systematic review and meta-analysis of randomized controlled trials. ( 30817582 )
2019
21
Associations of mood symptoms with NYHA functional classes in angina pectoris patients: a cross-sectional study. ( 30836983 )
2019
22
Comparative efficacy of Chinese herbal injections for angina pectoris: A Bayesian network meta-analysis of randomized controlled trials. ( 30935533 )
2019
23
Efficacy and Safety Evaluation of Taohong Siwu Decoction () for Patients with Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials. ( 30941683 )
2019
24
Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study. ( 30963332 )
2019
25
Neutrophil count as the centerpiece in the joined association networks of inflammatory and cell damage markers, and neuroendocrine stress markers in patients with stable angina pectoris following stenting. ( 30973928 )
2019
26
Endothelial Nitric Oxide Level as a Predictor of Coronary Complexity in Patients With Unstable Angina Pectoris. ( 31000423 )
2019
27
Ample evidence for statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention. ( 31000432 )
2019
28
Isolated congenital left ventricular diverticulum presenting as stable angina pectoris and surgical treatment. ( 31043976 )
2019
29
Assessment of Left Ventricular Ejection Fraction by Thallium-201 Myocardial SPECT-CT in Patients with Angina Pectoris: Comparison with 2D Echocardiography. ( 31057685 )
2019
30
Evaluating Serum Levels of Pentraxin-3, von Willebrand Factor and C-X-C Motif Chemokine Ligand 13 as Inflammatory Markers of Unstable Angina Pectoris. ( 31066256 )
2019
31
Advances in small-molecule therapy for managing angina pectoris in the elderly. ( 31107109 )
2019
32
Relationship Between Prodromal Angina Pectoris and Neutrophil-to Lymphocyte Ratio in Patients With ST Elevation Myocardial Infarction. ( 29735396 )
2019
33
Usefulness of Higher Levels of Cardiac Troponin T in Patients With Stable Angina Pectoris to Predict Risk of Acute Myocardial Infarction. ( 30146101 )
2018
34
Doppler Versus Thermodilution-Derived Coronary Microvascular Resistance to Predict Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction or Stable Angina Pectoris. ( 29132649 )
2018
35
The clinical significance of echo-attenuated plaque in stable angina pectoris compared with acute coronary syndromes: A combined intravascular ultrasound and optical coherence tomography study. ( 29908828 )
2018
36
A randomized, triple-blind trial of cardiac shock-wave therapy on exercise tolerance and symptoms in patients with stable angina pectoris. ( 29912782 )
2018
37
Cardiac Troponin T Concentrations, Reversible Myocardial Ischemia, and Indices of Left Ventricular Remodeling in Patients with Suspected Stable Angina Pectoris: a DOPPLER-CIP Substudy. ( 29959147 )
2018
38
The correlation between speckle tracking echocardiography and coronary artery disease in patients with suspected stable angina pectoris. ( 29961454 )
2018
39
Protein biomarkers and coronary microvascular dilatation assessed by rubidium-82 PET in women with angina pectoris and no obstructive coronary artery disease. ( 29981522 )
2018
40
Ascending Aortic Strain Analysis Using 2-Dimensional Speckle Tracking Echocardiography Improves the Diagnostics for Coronary Artery Stenosis in Patients With Suspected Stable Angina Pectoris. ( 29982229 )
2018
41
Tools to improve the diagnostic accuracy of exercise electrocardiograms in patients with atypical angina pectoris. ( 30024394 )
2018
42
Impact of statins preloading before PCI on periprocedural myocardial infarction among stable angina pectoris patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. ( 30056022 )
2018
43
Usefulness of Postsystolic Shortening to Diagnose Coronary Artery Disease and Predict Future Cardiovascular Events in Stable Angina Pectoris. ( 30077186 )
2018
44
Nicorandil improves clinical outcomes in patients with stable angina pectoris requiring PCI: a systematic review and meta-analysis of 14 randomized trials. ( 30079778 )
2018
45
The Relationship between Compound Danshen Dripping Pills with Isosorbide Mononitrate in the Treatment of Elderly Patients with Unstable Angina Pectoris. ( 30108652 )
2018
46
Epicardial Coronary Spasm in Women With Angina Pectoris and Unobstructed Coronary Arteries Is Linked With a Positive Family History: An Observational Study. ( 30122309 )
2018
47
Letter to the Editor: "Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris". ( 30124877 )
2018
48
Response to Letter to the Editor: "Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris". ( 30124923 )
2018
49
Effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris: Protocol for a systematic review. ( 30142757 )
2018
50
Management of stable angina pectoris in private healthcare settings in South Africa. ( 30152841 )
2018

Variations for Angina Pectoris

Expression for Angina Pectoris

LifeMap Discovery
Genes differentially expressed in tissues of Angina Pectoris patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 4.04 0.001
Search GEO for disease gene expression data for Angina Pectoris.

Pathways for Angina Pectoris

GO Terms for Angina Pectoris

Cellular components related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ACE APOA1 APOA2 CRP EDN1 IL6
2 blood microparticle GO:0072562 9.58 APOA1 APOA2 SERPINC1
3 endoplasmic reticulum lumen GO:0005788 9.56 APOA1 APOA2 IL6 SERPINC1
4 high-density lipoprotein particle GO:0034364 9.43 APOA1 APOA2
5 very-low-density lipoprotein particle GO:0034361 9.37 APOA1 APOA2
6 chylomicron GO:0042627 9.32 APOA1 APOA2
7 extracellular space GO:0005615 9.28 ACE APOA1 APOA2 CRP EDN1 IL6
8 spherical high-density lipoprotein particle GO:0034366 9.16 APOA1 APOA2

Biological processes related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.92 APOA1 APOA2 IL6 SERPINC1
2 response to drug GO:0042493 9.89 APOA1 APOA2 EDN1 HTR1B
3 cellular protein metabolic process GO:0044267 9.71 APOA1 APOA2 IL6 SERPINC1
4 cholesterol efflux GO:0033344 9.65 APOA1 APOA2
5 lipoprotein metabolic process GO:0042157 9.65 APOA1 APOA2
6 regulation of vasoconstriction GO:0019229 9.65 ACE EDN1
7 reverse cholesterol transport GO:0043691 9.64 APOA1 APOA2
8 high-density lipoprotein particle remodeling GO:0034375 9.64 APOA1 APOA2
9 vasoconstriction GO:0042310 9.63 EDN1 HTR1B
10 heart contraction GO:0060047 9.63 ACE TNNI3
11 positive regulation of renal sodium excretion GO:0035815 9.62 EDN1 NPPB
12 positive regulation of urine volume GO:0035810 9.61 EDN1 NPPB
13 regulation of blood vessel diameter GO:0097746 9.61 ACE NPPB
14 high-density lipoprotein particle assembly GO:0034380 9.6 APOA1 APOA2
15 phospholipid efflux GO:0033700 9.58 APOA1 APOA2
16 chylomicron assembly GO:0034378 9.58 APOA1 APOA2
17 high-density lipoprotein particle clearance GO:0034384 9.57 APOA1 APOA2
18 body fluid secretion GO:0007589 9.56 EDN1 NPPB
19 negative regulation of lipid storage GO:0010888 9.55 CRP IL6
20 positive regulation of cholesterol esterification GO:0010873 9.54 APOA1 APOA2
21 chylomicron remodeling GO:0034371 9.52 APOA1 APOA2
22 neutrophil mediated immunity GO:0002446 9.51 ACE IL6
23 negative regulation of hydrolase activity GO:0051346 9.49 APOA1 NOS3
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.48 APOA1 APOA2
25 peptidyl-methionine modification GO:0018206 9.46 APOA1 APOA2
26 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.43 EDN1 NOS3
27 regulation of intestinal cholesterol absorption GO:0030300 9.37 APOA1 APOA2
28 negative regulation of lipase activity GO:0060192 9.32 APOA1 APOA2
29 protein oxidation GO:0018158 9.26 APOA1 APOA2
30 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.16 APOA1 APOA2
31 regulation of blood vessel size GO:0050880 9.13 EDN1 NOS3 NPPB
32 regulation of blood pressure GO:0008217 8.92 ACE EDN1 NOS3 NPPB

Molecular functions related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol transporter activity GO:0017127 9.37 APOA1 APOA2
2 high-density lipoprotein particle binding GO:0008035 9.32 APOA1 APOA2
3 lipase inhibitor activity GO:0055102 9.26 APOA1 APOA2
4 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.16 APOA1 APOA2
5 apolipoprotein receptor binding GO:0034190 8.96 APOA1 APOA2
6 high-density lipoprotein particle receptor binding GO:0070653 8.62 APOA1 APOA2

Sources for Angina Pectoris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....